

Prevalence of sarcopenia in multi ethnics adults and the association with cognitive impairment: findings from West-China Health and Aging Trend Study

Xiaolei Liu

Sichuan University West China Hospital

Lisha Hou

Sichuan University West China Hospital

Xin Xia

Sichuan University West China Hospital

Yang Liu

Sichuan University West China Hospital

Zhiliang Zuo

Sichuan University West China Hospital

Yan Zhang

Sichuan University West China Hospital

Wanyu Zhao

Sichuan University West China Hospital

Qiukui Hao

Sichuan University West China Hospital

Jirong Yue

Sichuan University West China Hospital

birong dong (✉ birongdong123@outlook.com)

national clinical research center, West China Hospital, Sichuan University. <https://orcid.org/0000-0002-2601-5855>

Research article

Keywords: sarcopenia, aging, western China, multi-ethnic, cognitive impairment

Posted Date: December 13th, 2019

DOI: <https://doi.org/10.21203/rs.2.18809/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on February 17th, 2020. See the published version at <https://doi.org/10.1186/s12877-020-1468-5>.

Abstract

Background

Sarcopenia is a condition that is characterized by loss of muscle mass, muscle strength and muscle functional impairment with ageing. It is associated with poor health outcomes, premature death and a significant burden on the global health economy. The prevalence of sarcopenia in China is unknown since most of the studies are lack of uniform standard. The study was undertaken to study the prevalence of sarcopenia and the association with cognitive impairment among multi-ethnic adults aged 50 years old or older in western China.

Methods

We measured gait speed, handgrip strength and muscle mass by using bioelectrical impedance analysis (BIA) for all eligible participants and 4500 participants were eligible for the analysis. We defined sarcopenia using the diagnostic algorithm recommended by the Asian Working Group for Sarcopenia (AWGS) . We assessed the participants' cognitive functions using the 10-item Short Portable Mental Status Questionnaire (SPMSQ) . Relationships between sarcopenia and cognitive impairment were analyzed using univariate and multivariate analyses.

Results

Of 4500 participants (mean age 62.4 ± 8.3 years), 869 (19.31%) adults were sarcopenia. 446 (9.9%) participants were identified as having mild cognitive impairment, 144 (3.2%) adults were identified as having moderate/severe cognitive impairment. After adjusting for age, gender, ethnics and other potential cofounders, cognitive impairment was found to be independently associated with sarcopenia with a dosage effect (mild cognitive impairment: odds ratio [OR] : 1.52, 95% CI 1.18–1.95; moderate/severe cognitive impairment: OR: 3.26, 95% CI 2.23–4.76). After gender stratification, the association between mild cognitive impairment with sarcopenia in male is not significant, while is still significant in female. While the association between moderate/severe cognitive impairment is independently associated with sarcopenia in both male and female.

Conclusions

The prevalence rates of sarcopenia, mild cognitive impairment, moderate/severe cognitive impairment among the communities aged 50 or older in western China were 19.31%, 9.9% and 3.2%, respectively. Cognitive impairment was significantly associated with sarcopenia with a dosage effect, especially in female.

Background

Sarcopenia was first named in 1989, an age-associated loss of skeletal muscle mass and function¹. The 2010 European Working Group on Sarcopenia in Older People (EWGSOP) defines it as a type of

progressive, extensive reduction in skeletal muscle mass, muscle strength and skeletal muscle dysfunction, leading to a decline in body function and quality of life, and even death². It is generally characterized by decreased muscle mass and bone mass with aging, as well as skeletal muscle dysfunction, which in turn affects the normal physiological function and quality of life³. In 2016, sarcopenia was officially included in the ICD-10 disease code², marking the diagnosis of sarcopenia in the field of clinical medicine, which is considered as a disease with its unique characteristics. Besides, sarcopenia was considered as a mortality predictor in community-dwelling older adults, meaning that older adults with severe sarcopenia had an increased risk of death in the short term⁴.

The incidence of sarcopenia reported in different countries varies greatly depending on the method of measurement, the population surveyed, and the diagnostic criteria. Prevalence rates using EWGSOP definition vary from 1 to 29% in elderly community-dwelling populations and from 14 to 33% in long-term care populations in western countries⁵. While the prevalence of sarcopenia in Asia is 2.5%-45.7% using Asia Working Group for Sarcopenia (AWGS) definition⁶. However, many challenges remained to be solved in the future. Asia is made up of a great number of ethnicities. The majority of currently available studies have been published from eastern Asia. Therefore, more studies of sarcopenia in the south, southeastern, and western Asia should be promoted.

China is the most populous country in Asia with the world's largest aging population. By 2050, there will be 400 million Chinese citizens aged over 65 years old, and 150 million of whom will be over 80 years old⁷. Besides, China is a multi-ethnic country with 56 ethnics. The prevalence of sarcopenia in multi-ethnic western China is unknown. Screening and assessment of sarcopenia may provide an opportunity for early detection, intervention, and monitoring of the most vulnerable Chinese elders to reduce morbidity, prevent disability, and enable more effective use of health care resources in minority areas. Besides, although the association between sarcopenia and adverse health outcomes has been described, the interrelationship between cognitive impairment and sarcopenia in older people remains a controversy.

In this study, we got the cross-sectional data from the West-China Health and Aging Trend (WHAT), a longitudinal multi-center cohort research conducted in western China to assess the health and aging status in the multi-ethnic region. According to the diagnostic algorithm of AWGS, participants with low muscle mass as well as low muscle strength or physical performance were considered to have sarcopenia. We aimed to 1) evaluate the prevalence of sarcopenia according to the recommended criterion of the AWGS. 2) investigate the association between cognitive impairment and sarcopenia.

Methods

Participants

The current research is a cross-sectional analysis obtaining baseline data of the WHAT study collected from July to December in 2018. Data were collected from 4 provinces including Yunnan, Guizhou, Sichuan, and Xinjiang. All participants aged 50 years old or older were enrolled. Participants were

recruited by convenience and asked verbally by the researchers about their willingness to take part in the study. Before investigation, informed consent was signed and obtained by each participant. Initially, we recruited 7536 community-dwelling multi-ethnic Chinese aged 50 and older in total. 4500 participants did the bioelectrical impedance analysis (BIA) which is available for the selection of sarcopenia (Fig. 1).

Sarcopenia screening

Sarcopenia was measured by the recommended diagnostic algorithm of AWGS in which included three elements: muscle mass, muscle strength, and physical performance. Muscle mass was measured by the method of BIA and this has been verified reliability and validity in Chinese⁸. The BIA method adopted the INbody720 body composition instrument, which was widely used in the diagnosis of sarcopenia^{5,9,10}. Previous research did not observe statistical difference between MRI-measured and BIA-derived SM¹¹. And the cut-off value of appendicular skeletal muscle mass index (ASMI) was 7.0 kg/m² in men and, 5.7 kg/m² in women. While grip strength was used to evaluate muscle strength and the cut-off value was 26 kg in men and, 18 kg in women¹². Usual walking speed was measured and for sarcopenia definition, the cut-off value of gait speed was 0.8 m/s⁵.

Demographic information

Demographic information included age, gender, ethnics, marriage status, living status and education levels.

Daily lifestyles and chronic diseases

Smoking, alcohol drinking, and tea drinking habits were used to assess the daily lifestyles of the participants. Smoking status was categorized as smoking and no smoking. Alcohol and tea drinking status was categorized as drinking and no drinking. Sleep quality was assessed using Pittsburgh sleep quality index (PSQI). Scores > 5 are considered as poor self-reported sleep quality which was sensitive in distinguishing good vs. poor sleepers in Chinese¹³. Indoor housework and outdoor housework were also asked by the interviewers. A medical history of chronic disease was self-reported by the participants or their caregivers. These disease conditions included hypertension, coronary heart disease, chronic obstructive pulmonary disease, osteoarticular disease, tumor, stroke, diabetes mellitus, cataract, deaf and so on. Chronic diseases comorbidities were considered as having two or more kinds of chronic diseases.

Cognitive function, depressive symptoms and anxiety status

Cognitive status was measured using a 10-item Short Portable Mental Status Questionnaire (SPMSQ). For SPMSQ scoring, 0 ~ 2 indicated complete cognitive function, 3 ~ 4 indicated mild cognitive functional impairment, 5 ~ 7 indicated moderate cognitive function impairment, and 8 ~ 10 indicated severe cognitive function impairment. And this judgment was based on the educational level¹⁴. Depressive symptoms were assessed using the 15-item Geriatric Depression Scale (GDS-15). The scale, which contains 15 items that require only a yes/no answer, is the most widely used scale for the detection of

depression. GDS-15 scores ≥ 5 indicate depressive mood¹⁵. Anxiety status was assessed using Generalized Anxiety Disorder (GAD-7) questionnaire and the scores ≥ 5 was considered as having anxiety status¹⁶.

Statistical analysis

We test the normality of variables using R version 3.6.1. The measurement data is expressed by $X \pm SD$. For the normal distribution variables, the difference between the groups is compared by the independent sample T-test and the count data is expressed in %, using the χ^2 test. We used χ^2 test to determine whether the prevalence of cognitive impairment related factors was differed by sarcopenia status. Associations with a p-value of 0.1 or less in the univariate analysis were selected for the multiple regression analysis, which were used to estimate the odds ratio (OR) to identify associations between sarcopenia and cognition impairment after adjusting for potential confounders. A value of $P \leq 0.05$ (two-side) was considered to be statistically significant.

Results

Overall, we enrolled 4500 participants (1627 men and 2873 women) aged 50 years old or older in the study. The mean age of the group was 62.4 (SD:8.3) years. Most of the participants were female (63.8%). 869 (19.31%) adults were sarcopenia, 446 (9.9%) participants were identified as having mild cognitive impairment, 144 (3.2%) adults were identified as having moderate/severe cognitive impairment. An overview of clinical and sociodemographic data, anthropometric measures, cognition, depression, lifestyle factors, and chronic diseases are given in table 1. Compared to the subjects without sarcopenia, those with sarcopenia were on average older, lower educational degree, living alone, bad marriage status (windowed or divorced), poor sleep quality, lower physical activities (indoor housework or outdoor housework), more smoking, less drinking tea, chronic diseases comorbidities burden, higher prevalence of depression and cognitive impairment (Table 1). And the prevalence of different ethnics varies significantly. While drinking alcohol and the prevalence of anxiety status is not significant between sarcopenia group and non-sarcopenia group (Table 1).

Characteristics		No Sarcopenia n=3631	Sarcopenia n=869	T/ χ^2	p value
Age,year,mean(\pm SD)		61.0(7.5)	67.9(8.8)	21.39	<.001
50 \leq Age \leq 65, No(%)		2501 (69.5)	321 (37.8)	297.99	<.001
65 \leq Age, No (%)		1099 (30.5)	529 (62.2)		
Gender	Male	1268(34.9)	359(41.3)	12.41	<.001
	Female	2363(65.1)	510(58.7)		
Ethnics				83.15	<.001
Han,No(%)		1506(41.5)	431(49.6)		
Zang,No(%)		1009(27.8)	224(25.8)		
Qiang,No(%)		926(25.5)	124(14.3)		
Yi,No(%)		139(3.8)	74(8.5)		
Others,No(%)		56(1.6)	17(2.0)		
Education,No(%)				49.17	<.001
No formal education		972(26.8)	322(37.1)		
Elementary school		1161(32.0)	287(33.0)		
Middle school		787(21.7)	134(15.4)		
High school and above		711(19.6)	126(14.5)		
Marital status, No (%)				56.84	<.001
Single		23 (0.7)	8 (1.0)		
Married		2965 (86.0)	628 (76.0)		
Divorced		52 (1.5)	15 (1.8)		
Widowed		409 (11.9)	175 (21.2)		
Anthropometric measures					
Grip strength, mean(\pm SD)		23.0(8.7)	17.6(6.8)	19.94	<.001
Gait speed, mean(\pm SD)		0.88(0.3)	0.74(0.3)	13.41	<.001
ASMI, mean(\pm SD)		6.8(0.9)	5.7(0.7)	40.14	<.001
Life-styles					
Living alone	Yes	153(4.2)	57(6.6)	8.67	.003
	No	3478(95.8)	812(93.4)		
sleep quality	PQSI \geq 5	1595(46.3)	420(51.0)	5.90	.015
	No(%)	PQSI \leq 5	1848(53.7)		
Drinking Tea \square	Yes	1672(48.7)	373(45.5)	2.72	.099
	No (%)	No	1762(51.3)		
Drinking alcohol \square No (%)	Yes	876(25.5)	195(23.8)	1.08	.299
	No (%)	No	2559(74.5)		
Smoking history	Yes	551(16.0)	187(22.8)	21.16	<.001
	No(%)	No	2885(84.0)		
Indoor housework	No	952(27.8)	335(41.2)	55.80	<.001
	No(%)	Yes	2472(72.2)		
Outdoor housework	No	1974(57.8)	511(63.1)	7.54	.006
	No(%)	Yes	1441(42.2)		
Number of chronic diseases				4.92	.027
0 or 1, No (%)		934(25.7)	192(22.1)		
\geq 2, No(%)		2697(74.3)	677(77.9)		

Depressive	GDS-15 \leq 5	2816(77.6)	639(73.5)	6.36	.012
status, No (%)	GDS-15 \geq 5	815(22.4)	230(26.5)		
Anxiety	GAD-7 \leq 5	2950(81.2)	708(81.5)	0.02	.877
status, No (%)	GAD-7 \geq 5	681(18.8)	161(18.5)		
Cognitive function, No (%)				92.59	.001
Complete cognitive function		3023(88.1)	637(77.7)		
Mild impairment, No (%)		331(9.7)	115(14.0)		
Moderate-severe impairment,		76(2.2)	68(8.3)		
No (%)					

Note. Means \pm standard deviation was shown. Others=other nationalities including Zhuang, Manchu, Hui, Mongolia, Tujia nationalities. Data are shown using % or mean (standard deviation). P values were calculated with chi-squared tests and Student's t tests for categorical and continuous variables, respectively.

Table 1

Comparisons of demographic characteristics, anthropometric measures, life-styles, chronic diseases, depression, and cognitive impairment of the study participants with and without sarcopenia. (N=4500)

Table 2 shows the association between sarcopenia and cognitive impairment using multiple logistic regression in three models. In model 1 which only adjusted age, sex and ethnics, cognitive impairment (mild: OR 1.62, 95% CI 1.27–2.07, $P < .001$; moderate/severe: OR 3.72, 95% CI 2.57–5.38, $P < .001$) was significantly associated with sarcopenia (Table 2). After adding adjusting the marriage status, living alone, life-style factors, physical activities and sleep quality in model 2, results showed that sarcopenia was still significantly associated with mild cognitive impairment (OR: 1.55, 95% CI, 1.21–1.99, $P = .001$) and moderate/severe cognitive impairment (OR: 3.48, 95% CI, 2.39–5.07, $P < .001$) (Table 2). And this is consistent in the fully adjusted model 3 after adding chronic diseases comorbidities and depressive status which showed sarcopenia was significantly associated with mild cognitive impairment (OR: 1.52, 95% CI, 1.18–1.95, $P = .001$) and moderate/severe cognitive impairment (OR: 3.26, 95% CI, 2.23–4.76, $P < .001$). Besides, we analyzed the association between three elements of sarcopenia and cognition function separately. And it shows that cognitive impairment was significantly associated with grip strength, gait speed and ASMI separately with a dosage effect. After gender stratification in fully adjusted model, mild cognitive impairment is not significantly associated with sarcopenia in male, but is still significant in female. While moderate/severe cognitive impairment in male has a higher odds ratio than female (male: OR: 5.25, 95% CI, 2.23–12.39, $P < .001$; female: OR: 2.79, 95% CI, 1.81–4.30, $P < .001$) (Table 3).

Table 2

Multiple regression analysis of sarcopenia and the three factors of sarcopenia (grip strength, gait speed, ASMI) with cognitive impairment among multi-ethnics in the west China communities. (N = 4500)

Sarcopenia		Model 1, OR(95%CI), p value	Model 2, OR(95%CI), p value	Model 3, OR(95%CI), p value
Cognitive impairment	No	1.0(Ref)	1.0(Ref)	1.0(Ref)
	Mild	1.62(1.27–2.07), \leq .001	1.55(1.21–1.99), .001	1.52(1.18–1.95), .001
	Moderate-severe	3.72(2.57–5.38), \leq .001	3.48(2.39–5.07), \leq .001	3.26(2.23–4.76), \leq .001
Grip strength				
Cognitive impairment	No	1.0(Ref)	1.0(Ref)	1.0(Ref)
	Mild	1.54(1.25–1.91), \leq .001	1.47(1.19–1.82), \leq .001	1.43(1.16–1.77), .001
	Moderate-severe	2.41(1.63–3.55), \leq .001	2.24(1.51–3.31), \leq .001	2.11(1.42–3.12), \leq .001
Gait speed				
Cognitive impairment	No	1.0(Ref)	1.0(Ref)	1.0(Ref)
	Mild	1.59(1.29–1.96), \leq .001	1.51(1.22–1.86), \leq .001	1.48(1.20–1.83), \leq .001
	Moderate-severe	1.93(1.34–2.78), \leq .001	1.78(1.23–2.58), .002	1.71(1.78–2.48), .005
ASMI				
Cognitive impairment	No	1.0(Ref)	1.0(Ref)	1.0(Ref)
	Mild	1.43(1.13–1.80), .003	1.39(1.10–1.76), .006	1.36(1.08–1.73), .010
	Moderat-severe	3.05(2.13–4.37), \leq .001	2.89(2.01–4.16), \leq .001	2.74(1.90–3.95), \leq .001

Table 3

Association of cognitive impairment and sarcopenia among multi ethnics in the west China communities after gender stratification. (N = 4500)

Variables		Adjusted OR (95% CI)	P value
Male			
Cognitive impairment	Mild	1.54 (0.96; 2.48)	.075
	Moderate-severe	5.25 (2.23; 12.39)	∞.001
Female			
Cognitive impairment	Mild	1.50 (1.11; 2.03)	.008
	Moderate-severe	2.79 (1.81; 4.30)	∞.001
Note. Adjusted odds ratios were computed by adjusting for age, ethnics, marriage status, life-style factors (smoking, drinking tea), living alone, sleep quality, chronic diseases comorbidities, depressive status; CI, confidence interval; OR, odds ratio.			

Discussion

According to reports from different countries in Asia, the prevalence of sarcopenia varies from 7.8%-35.3% depending on different diagnostic instruments, different age and living conditions of the study participants in each study¹⁷. In our study, the mean age is 62.4 (SD ± 8.3) and the prevalence of sarcopenia is 19.31%, which was similar to a cohort study in Taiwan using the AWGS diagnostic criteria that the prevalence of sarcopenia was 21% in participants aged 75 years and older¹⁸. Another cohort study in northern Taiwan included 302 individuals (157 men and 145 women) aged 65 years and older, and the prevalence of sarcopenia in that study was 18.6% in elderly women and 23.6% in elderly men using BIA analysis¹¹. A previous study in Chengdu found approximately 10% community-dwelling elderly have sarcopenia in a number of 947 residents aged ≥ 60 years old which is also estimated by the BIA analysis¹⁹. And the prevalence of sarcopenia was 12.3% in Chinese men and 7.6% in Chinese women aged 70 years and older in Hongkong estimated by dual-energy X-ray absorptiometry²⁰. This study found a higher prevalence than Chengdu and Hongkong. The reason might be that most participants were living in the village that were poorer and have lower education level even through the mean age of our study is lower than the previous studies. This shows sarcopenia are happening younger in rural areas. And the difference may also be derived from the geographical and diagnostic criteria for sarcopenia and the difference in cognitive function diagnostic criteria. Besides, our study also found that advanced age with a dose response effect associated with sarcopenia and this is compatible with many other studies²⁰⁻²². Moreover, our study found that the prevalence of sarcopenia in male is higher than in the female. This is not consistent with other previous studies which showed Chinese women may be more vulnerable to

severe sarcopenia in old age than men²³. The reason might be that the mean age of male is older than the female in our study.

Our findings revealed that sarcopenia was significantly associated with cognition impairment in the multi-ethnic western Chinese population, independent of age, gender, ethnics, marriage status, lifestyle factors, indoor or outdoor housework, sleep quality, chronic diseases comorbidities and depression status. The cognitive impairment might be an independent risk factor of sarcopenia and has a dosage effect. This is compatible with several other studies that shows a positive relationship between cognitive impairment and sarcopenia²⁴⁻²⁶. While in the EPIDOS cohort study, sarcopenia was not shown to be associated with cognitive impairment in elderly women²⁷. Several possible mechanisms in many studies could explain this association. Firstly, cognitive impairment leads to reduced physical activity and dietary intake, which could trigger excessive muscle loss in older adults, accelerating sarcopenia²⁸. Secondly, low-grade inflammation is considered to be associated with both sarcopenia and cognitive impairment. Interleukin-6 (IL-6) and tumor necrosis factor- α (TNF- α) have also been reported as inflammatory parameters, which are the important factors to lead to sarcopenia²⁹ and the development of cognitive impairment³⁰. Third, excessive oxidative stress related to chronic diseases also play important roles in age-related muscle atrophy, interfering with the balance between protein synthesis and breakdown, causing mitochondrial dysfunction, inducing apoptosis, and lead to sarcopenia³¹. While products of oxidative and nitrosative stress accumulate with aging, which is also the main risk factor for cognition impairment³². In the end, cognitive impairment reinforces and emphasizes the neuronal changes in the central nervous system leading to changes in the levels and activity of neurotransmitters, which together with the inadequate distribution of oxygen to the brain, lead to a reduction in motor units and in the ability to maintain muscle activation, which might be related to sarcopenia³³. Thus, there exists a close relationship between sarcopenia and cognitive impairment which share some common mechanisms.

Besides, our study found that the association between sarcopenia with moderate/severe cognitive impairment in male has a higher odds ratio than female which might be related to hormone regulation. And moderate/severe cognitive impairment is positively related to sarcopenia in women and men, while the mild cognitive impairment seems not be related to sarcopenia in male. And a recent study indicated significant associations of sarcopenia and physical frailty with cognitive decline was could be more easier to be found in females³⁴. One study explained this sex differences may be partly due to systemic inflammation³⁵. A larger sample prospective cohort studies are required to illustrate gender differences.

Moreover, our study analyzed the association between cognitive impairment and the three elements in the fully regression model and it shows significant association in grip strength, gait speed and ASMI with a dosage effect separately. And this is consistent with recent studies. A study had shown that handgrip strength could be a means of monitoring progression of cognitive decline³⁶. And some longitudinal studies found that those with slower walking speeds and a greater decline in speed over time were at greater risk of developing dementia and could predict transitioning from mild to severe cognitive impairment^{37,38}. However, for the element of ASMI, recent study found that Lower-extremity functioning,

rather than ASMI, is closely related to multiple cognitive domains³⁹. While low muscle mass was found to be predictors of long-term mortality in nonagenarian and centenarian women⁴⁰. Whether ASMI could be used as a predictor of cognitive impairment required more studies.

This is a large study to assess sarcopenia defined by the AWGS criteria and its association with cognitive impairment in multi-ethnic western China, adjusting the analysis for relevant confounders, such as sociodemographic characteristics, marriage status, lifestyle factors, and chronic diseases comorbidities. Nonetheless, this study presents some limitations. It is derived from a cross-sectional study, in such a way that it is not possible to conclude the existence of a causal association between sarcopenia in the participants and the associated factors mentioned here, which is feasible in longitudinal designs. Although regression models were adjusted for many variables, residual confounding is still possible. In addition, chronic disease information, cognition, and depression adjustment come from self-reported questionnaires, and in spite that all the data in the questionnaires have been previously validated, this information should be treated with caution. In the end, we conducted a centralized investigation, not a household survey in which most of the participants who can come by themselves are relatively healthy people. As a result of it, there exists offset in the result of prevalence. However, despite these limitations, this study has enough samples for adjustment of the regression models to major confusion factors of clinical interests. Moreover, it presented similar results to those found in studies with a more robust methodology.

Conclusions

This study demonstrated that the prevalence of sarcopenia was 19.31% among 4500 multi-ethnic participants aged 50 years old or older in western China and sarcopenia was significantly associated with cognitive impairment with a dosage effect, especially in female. This is a large cross-sectional study in multi-ethnic western China which is significant to further study of sarcopenia in China and filled up the prevalence of sarcopenia in the western Asia which is important in promoting Asia sarcopenia research as Asia is made up of a great number of ethnicities. Moreover, considering the health consequences of sarcopenia is increasingly being recognized, further longitudinal study is required to explore the causal relationship between sarcopenia with cognitive impairment.

Abbreviations

BIA: bioelectrical impedance analysis.

AWGS: Asian Working Group for Sarcopenia.

SPMSQ: Short Portable Mental Status Questionnaire.

OR: odds ratio.

EWGSOP: European Working Group on Sarcopenia in Older People.

WHAT: West-China Health and Aging Trend.

ASMI: skeletal muscle mass index.

GDS-15:15-item Geriatric Depression Scale.

GAD-7: Generalized Anxiety Disorder.

IL-6: Interleukin-6.

TNF- α : tumor necrosis factor- α .

Declarations

Ethics approval and consent to participate

The current research was approved by the Ethical Review Committee of West China Hospital of Sichuan University with the committee's reference number 2017(445) and the registration number is ChiCTR 1800018895. Participants were recruited by convenience and asked verbally by the researchers about their willingness to take part in the study. Before investigation, informed consent was signed and obtained by each participant.

Competing Interest

The authors report no conflicts of interest in this work.

Funding

Supported by 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University; National Key R&D Program of China (2017YFC0840100 and 2017YFC0840101); Sichuan Science and Technology Program(2018TJPT0015 and 2018JY0094). The funding body had no role in the design of the study and collection, analysis, interpretation of data or in writing the manuscript.

Authors' contributions

XL designed the study and wrote the paper. LH, XX, YL, ZZ, YZ, WZ take part in the interpretation of data. QH, JY, BD reviewed and edited the manuscript. All authors have read and approved the manuscript.

Availability of Data and Materials

The datasets generated and analyzed during the current study are not publicly available due to this is a newly database which has a lot of important information and we are applying some important projects based on this. But this dataset will be available two years later and is also available now from the corresponding author on a reasonable request.

Consent to publish

Not applicable

Acknowledgements

We thank all the volunteers for the participation and personnel for their contribution in the WHAT study.

References

1. Rosenberg IH. Sarcopenia: origins and clinical relevance. *The Journal of nutrition*. May 1997;127(5 Suppl):990s-991s.
2. Cruz-Jentoft AJ, Jean Pierre B, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age & Ageing*. 2010.
3. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. *J Am Med Dir Assoc*. May 2011;12(4):249-256.
4. Bachettini NP, Bielemann RM, Barbosa-Silva TG, Menezes AMB, Tomasi E, Gonzalez MC. Sarcopenia as a mortality predictor in community-dwelling older adults: a comparison of the diagnostic criteria of the European Working Group on Sarcopenia in Older People. Oct 4 2019.
5. Cruz-Jentoft AJ, Francesco L, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). *Age & Ageing*. 2014;43(6):748-759.
6. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc*. Feb 2014;15(2):95-101.
7. Fang EF, Scheibye-Knudsen M, Jahn HJ, et al. A research agenda for aging in China in the 21st century. *Ageing research reviews*. Nov 2015;24(Pt B):197-205.
8. Wang H, Hai S, Cao L, Zhou J, Liu P, Dong BR. Estimation of prevalence of sarcopenia by using a new bioelectrical impedance analysis in Chinese community-dwelling elderly people. *BMC geriatrics*. Dec 28 2016;16(1):216.
9. Tosato M, Marzetti E, Cesari M, et al. Measurement of muscle mass in sarcopenia: from imaging to biochemical markers. *Aging clinical and experimental research*. Feb 2017;29(1):19-27.
10. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*. Jul 1 2019;48(4):601.
11. Chien MY, Huang TY, Wu YT. Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan. *Journal of the American Geriatrics Society*. Sep 2008;56(9):1710-1715.
12. Landi F, Calvani R, Tosato M, et al. Age-Related Variations of Muscle Mass, Strength, and Physical Performance in Community-Dwellers: Results From the Milan EXPO Survey. *J Am Med Dir Assoc*. Jan 2017;18(1):88.e17-88.e24.
13. Tsai PS, Wang SY, Wang MY, et al. Psychometric evaluation of the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary insomnia and control subjects. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. Oct 2005;14(8):1943-1952.
14. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. *Journal of the American Geriatrics Society*. Oct 1975;23(10):433-441.
15. Lim PP, Ng LL, Chiam PC, Ong PS, Ngui FT, Sahadevan S. Validation and comparison of three brief depression scales in an elderly Chinese population. *International journal of geriatric psychiatry*. Sep

2000;15(9):824-830. 16. Swinson RP. The GAD-7 scale was accurate for diagnosing generalised anxiety disorder. *Evidence-based medicine*. Dec 2006;11(6):184. 17. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. *Journal of cachexia, sarcopenia and muscle*. Dec 2010;1(2):129-133. 18. Lin CC, Lin WY, Meng NH, et al. Sarcopenia prevalence and associated factors in an elderly Taiwanese metropolitan population. *Journal of the American Geriatrics Society*. Mar 2013;61(3):459-462. 19. Wang H, Hai S, Liu Y, et al. [Prevalence of Sarcopenia and Associated Factors in Community-dwelling Elderly Populations in Chengdu China]. *Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition*. Mar 2019;50(2):224-228. 20. Lau EM, Lynn HS, Woo JW, Kwok TC, Melton LJ, 3rd. Prevalence of and risk factors for sarcopenia in elderly Chinese men and women. *The journals of gerontology. Series A, Biological sciences and medical sciences*. Feb 2005;60(2):213-216. 21. Yu R, Wong M, Leung J, Lee J, Auyeung TW, Woo J. Incidence, reversibility, risk factors and the protective effect of high body mass index against sarcopenia in community-dwelling older Chinese adults. *Geriatrics & gerontology international*. Feb 2014;14 Suppl 1:15-28. 22. Lee JS, Auyeung TW, Kwok T, Lau EM, Leung PC, Woo J. Associated factors and health impact of sarcopenia in older Chinese men and women: a cross-sectional study. *Gerontology*. 2007;53(6):404-410. 23. Lu X, Chu H, Wang L, et al. Age- and sex-related differences in muscle strength and physical performance in older Chinese. Jul 2 2019. 24. Burns JM, Johnson DK, Watts A, Swerdlow RH, Brooks WM. Reduced lean mass in early Alzheimer disease and its association with brain atrophy. *Archives of neurology*. Apr 2010;67(4):428-433. 25. Hsu YH, Liang CK, Chou MY, et al. Association of cognitive impairment, depressive symptoms and sarcopenia among healthy older men in the veterans retirement community in southern Taiwan: a cross-sectional study. *Geriatrics & gerontology international*. Feb 2014;14 Suppl 1:102-108. 26. Nishiguchi S, Yamada M, Shirooka H, et al. Sarcopenia as a Risk Factor for Cognitive Deterioration in Community-Dwelling Older Adults: A 1-Year Prospective Study. *J Am Med Dir Assoc*. Apr 1 2016;17(4):372.e375-378. 27. Abellan van Kan G, Cesari M, Gillette-Guyonnet S, et al. Sarcopenia and cognitive impairment in elderly women: results from the EPIDOS cohort. *Age Ageing*. Mar 2013;42(2):196-202. 28. Roubenoff R. Exercise, sarcopenia, cognition, and mood. *Nestle Nutrition workshop series. Clinical & performance programme*. 2002;6:151-159; discussion 160-152. 29. Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. *Current opinion in clinical nutrition and metabolic care*. Jan 2012;15(1):12-22. 30. Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? *Journal of neuroimmunology*. Feb 1 2000;103(1):97-102. 31. Meng SJ, Yu LJ. Oxidative stress, molecular inflammation and sarcopenia. *International journal of molecular sciences*. Apr 12 2010;11(4):1509-1526. 32. Mangialasche F, Polidori MC, Monastero R, et al. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. *Ageing research reviews*. Oct 2009;8(4):285-305. 33. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. *Journal of the American Geriatrics Society*. Jun 2006;54(6):991-1001. 34. Ohta Y, Nomura E, Hatanaka N, et al. Female dominant association of sarcopenia and physical frailty in mild cognitive impairment and Alzheimer's disease. *Journal of clinical neuroscience : official journal of the*

Neurosurgical Society of Australasia. Aug 20 2019. 35. Canon ME, Crimmins EM. Sex differences in the association between muscle quality, inflammatory markers, and cognitive decline. *The journal of nutrition, health & aging*. Aug 2011;15(8):695-698. 36. Fritz NE, McCarthy CJ, Adamo DE. Handgrip strength as a means of monitoring progression of cognitive decline - A scoping review. *Ageing research reviews*. May 2017;35:112-123. 37. Hoogendijk EO, Rijnhart JJM, Skoog J, et al. Gait speed as predictor of transition into cognitive impairment: Findings from three longitudinal studies on aging. *Experimental gerontology*. Nov 18 2019;129:110783. 38. Hackett RA, Davies-Kershaw H, Cadar D, Orrell M, Steptoe A. Walking Speed, Cognitive Function, and Dementia Risk in the English Longitudinal Study of Ageing. *Journal of the American Geriatrics Society*. Sep 2018;66(9):1670-1675. 39. Ishii H, Makizako H, Doi T, Tsutsumimoto K, Shimada H. Associations of Skeletal Muscle Mass, Lower-Extremity Functioning, and Cognitive Impairment in Community-Dwelling Older People in Japan. *The journal of nutrition, health & aging*. 2019;23(1):35-41. 40. Wang H, Hai S, Liu Y, Liu Y, Dong B. Skeletal Muscle Mass as a Mortality Predictor among Nonagenarians and Centenarians: A Prospective Cohort Study. *Scientific reports*. Feb 20 2019;9(1):2420.

Figures




Figure 1

Flow chart of study participants. Note. Initially a total of 7536 community-dwelling multi-national Chinese aged 50 or older were recruited, 4500 participants did bioelectrical impedance analysis (BIA) were analyzed in this study. Among them, 1560 participants without low gait speed and low grip strength, 2071 participants without low ASMI and 869 participants met the AWGS criteria of sarcopenia.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [STROBEchecklistcrosssectional.doc](#)